In 2004, it was discovered that the reason why some patients with adenocarcinomas of the lung responded in spectacular form to treatment with tyrosine kinase inhibitors (TKIs) of EGFR was specifically due to the existence of activating mutations of this gene [1]–[3]. This evidence concerns the gene EGFR and lung adenocarcinoma.